Cardiol Therapeutics shares rise 7.48% premarket after positive ARCHER trial results for CardiolRx™.

Cardiol Therapeutics Inc. rose 7.48% in premarket trading, driven by the announcement of topline results from the ARCHER trial, which showed a notable improvement in the primary endpoint of left ventricular (LV) extracellular volume (ECV) favoring CardiolRx™ over placebo. The reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass. These results provide compelling clinical proof of concept for CardiolRx™ and strongly support advancing its clinical development in cardiomyopathies, heart failure, and myocarditis.